Recent News

• 03.28.2025 - FDA Issues Complete Response Letter for Etripamil for PSVT
• 03.28.2025 - FDA Issues Complete Response Letter for Etripamil for PSVT
• 03.20.2025 - Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology
• 03.20.2025 - Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology
• 03.13.2025 - Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
• 03.13.2025 - Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
• 03.04.2025 - TD Cowen 45th Annual Health Care Conference
• 03.04.2025 - TD Cowen 45th Annual Health Care Conference
• 03.04.2025 - Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.04.2025 - Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 03.28.2025 - EX-99.1 EX-99.1
• 03.28.2025 - 8-K Current report
• 03.19.2025 - 8-K Current report
• 03.18.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.18.2025 - 8-K Current report
• 03.13.2025 - 8-K Current report
• 03.13.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.13.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.13.2025 - EX-99.1 EX-99.1